01 / DESIGN
What was studied?
This randomized trial studied people with HIV and non-alcoholic fatty liver disease. The primary comparison assessed liver fat after 12 months of tesamorelin or placebo.
02 / FINDINGS
What did the researchers report?
The tesamorelin group had a greater reduction in measured liver fat. Localized administration-site complaints were more common, while measured glucose changes did not differ between groups at 12 months.
03 / LIMITS
How should it be interpreted?
This small study does not establish long-term liver outcomes or applicability to everyone with fatty liver. A change in liver fat is not equivalent to proof of preventing cirrhosis or other clinical complications.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.